Precision And Prevention Key To Future Of Alzheimer’s Treatment
A Look At Novel Approaches In The Alzheimer’s Pipeline
While a so-called disease modifying treatment has entered the market for the first time, in the form of Biogen’s Aduhelm, Alzheimer’s disease is unlikely to be cured by one drug alone. In Vivo explores the array of approaches to AD drug development, drawing on interviews with industry leaders and pipeline data.
You may also be interested in...
Emerging Company Profile: Swedish biotech AlzeCure is developing a portfolio of small-molecule drug candidates for diseases affecting the central nervous system, including Alzheimer’s disease and pain.
A selection of articles you might have missed from July 2021, including exclusive interviews with industry leaders and a deep dive into the RNA therapy pipeline.
With digital therapies and devices seeing widespread adoption in response to lockdown limitations during the COVID-19 pandemic, Kaiku Health is in a strong position to expand its patient monitoring software. CEO Lauri Sippola spoke with In Vivo about the platform and the company’s plans for 2021 and beyond.